U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Clinical Outcome Assessment (COA) Qualification Program
  6. DDT COA #000133: Small Cell Lung Cancer PRO
  1. Clinical Outcome Assessment (COA) Qualification Program

DDT COA #000133: Small Cell Lung Cancer PRO

Clinical Outcome Assessments (COA) Qualification Submissions
Office of Oncologic Diseases (OOD)
Division of Oncology 2 (DO2)

DDT COA Number
DDT COA #000133

Instrument Name
Small cell lung cancer (SCLC) symptom measure

Small cell lung cancer

Concept of Interest
SCLC symptom severity

Context of Use
Adult patients (> 18 years) with clinician-confirmed diagnosis of limited or extensive stage SCLC with Eastern Cooperative Oncology Group performance status of 0 to 2 regardless of the lines of therapy being administered

COA Type

Qualification Stage
Letter of Intent-Accepted

Critical Path Institute: Patient- Reported Outcome (PRO) Consortium, Small Cell Lung Cancer Working group

Sonya Eremenco

Date Accepted into CDER’s COA Qualification Program
July 6, 2020

Submission and Regulatory Correspondence History

Qualification Submission Date FDA Submission Decision & Recommendations Date
Letter of Intent 4/28/20 FDA Response (Accepted) 7/6/20
Back to Top